Quick-release bromocriptine for treatment of type 2 diabetes

Current Drug Delivery

Volumn 8, Issue 5, 2011, Pages 511-516

  Mikhail, Nasser ^a  

^a OLIVE VIEW UCLA MEDICAL CENTER   (United States)

Author keywords

Bromocriptine; Cabergoline; Diabetes; Dopamine agonist

Indexed keywords

BROMOCRIPTINE MESILATE; DOPAMINE; ERGOT DERIVATIVE; HEMOGLOBIN A1C; METFORMIN; METOCLOPRAMIDE; NEUROLEPTIC AGENT; PLACEBO; SULFONYLUREA; SUMATRIPTAN;

ADD ON THERAPY; ARTICLE; BODY WEIGHT; CARDIOVASCULAR EFFECT; CIRCADIAN RHYTHM; CONTROLLED RELEASE FORMULATION; DIZZINESS; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HUMAN; HYPOGLYCEMIA; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SIDE EFFECT; SOMNOLENCE; SYNCOPE; TREATMENT INDICATION; VOMITING;

BLOOD GLUCOSE; BROMOCRIPTINE; DIABETES MELLITUS, TYPE 2; FASTING; HUMANS; HYPOGLYCEMIC AGENTS; PLACEBOS; POSTPRANDIAL PERIOD;

EID: 80051748905     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/156720111796642255     Document Type: Article

References (26)

1. Landgraf, R.; Landgraf-Leurs, M.M.C.; Weissman, A.; Horl, R.; von Werder, K.; Scriba, P.C. Prolactin, a diabetogenic hormone. Diabetologia, 1977, 13, 99-104.
2. Barnett, A.H.; Chapman, C.; Gailer, K.; Hayter, C.J. Effect of bromocriptine on maturity onset diabetes. Postgrad. Med. J., 1980, 56, 11-14.
3. Katz, E.J.; Donald, R.A.; Reaven, D.W.; Espiner, E.A. Lack of effect of hyperprolactinemia on glucose disposal and insulin secretion in patients with prolactinomas. Horm. Metab. Res., 1981, 13, 667-669.
4. Scobie, I.N.; Kesson, C.M.; Ratcliffe, J.G.; Maccuish, A.C. The effects of prolonged bromocriptine administration on PRL secretion GH and glycaemic control in stable insulin-dependent diabetes mellitus. Clin. Endocrinol., 1983, 18, 179-185.
5. Yavuz, D.; Deyneli, O.; Akpinar, I.; Yildiz, E.; Gozu, H.; Sezgin, O.; Haklar, G.; Aklam, S. Endothelial function, insulin sensitivity, and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur. J. Endocrinol., 2003, 149, 187-193.
6. Kok, P.; Roelfsema, F.; Frolich, M.; van Pelt, J.; Stokkel, M.P.M.; Meinders, E.; Pijl, H. Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women. Am. J. Physiol. Endocrinol. Metab., 2006, 291, E1038-E1043.
7. Serri, O.; Li, L.; Mamputu, J.; Beauchamp, M.; Maingrette, F.; Renier, G. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin. Endocrinol., 2006, 64, 366-370.
8. Berinder, K.; Nystrom, T.; Hobye, C.; Half, K.; Hulting, A. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary, 2010, Dec 3. [Epub ahead of print]. Accessed February 3rd, 2011
9. dos Santos Silva, C.M.; Barbosa, F.R.P.; Lima, G.A.B.; Warszawski, L.; Fontes, R.; Domingues, R.C.; Gadelha, M.R. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity, 2010, Jun 17. [Epub ahead of print]. Accessed February 3rd, 2011.
10. Cycloset (bromocriptine mesylate). Prescribing information, 2009. VeroScience.
11. Kerr, J.L.; Timpe, E.M.; Petkewicz, K. Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus. Ann. Pharmacother., 2010, 44, 1777-1785.
12. Wasada, T.; Kawahara, R.; Iwamoto, Y. Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients. Diabetes Care, 2000, 23, 1039-1040.
13. Pijl, H.; Ohashi, S.; Matsuda, M.; Miyazaki, Y.; Mahankakali, A.; Kumar, V.; Pipek, R.; Iozzo, P.; Lancaster, J.L.; Cincotta, A.; De- Fronzo, R.A. Bromocriptine. A novel approach to the treatment of type 2 diabetes. Diabetes Care, 2000, 23, 1154-1161.
14. Kamath, V.; Jones, C.N.; Yip, J.C.; Varasteh, B.B.; Cincotta, A.H.; Reaven, G.M.; Chen, Y.I. Effects of a quick release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care, 1997, 20, 1697-1701.
15. Luo, S.; Liang, Y.; Cincotta, A.H. Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucoseintolerant state in hamsters. Neuroendocrinology, 1999, 69, 160-166.
16. Holt, R.I.; Barnett, A.H.; Bailey, C.J. Bromocriptine: old drug, new formulation and new indication. Diabetes Obes. Metab., 2010, 12, 1048-1057.
17. Scranton, R.; Cincotta, R. Bromocriptine-unique formulation of a dopamine agonist for the treatment of type 2 diabetes. Expert Opin. Pharmacother., 2010, 11, 269-279.
18. Parlodel (bromocriptine mesylate) Package insert, 2003. Novartis Pharmaceuticals Corporation, Suffern, New York, USA.
19. Maurer, G.; Schreier, E.; Delaborde, S.; Nufer, R.; Shukla, A.P. Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination, and metabolism. Eur. J. Drug Metab. Pharmacokinet., 1983, 8, 51-62.
20. Parkes, D. Drug Therapy. Bromocriptine. N. Engl. J. Med., 1979, 301, 873-878.
21. Meier, A.H.; Cincotta, A.H.; Lovell, W.C. Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics. Experientia, 1992, 48, 248-253.
22. Cincotta, A.H.; Meier, A.H. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care, 1996, 6, 667-670.
23. Cincotta, A.H.; Meier, A.H.; Cincotta, M. Bromocriptine improves glycaemic control and serum lipid profile in obese type 2 diabetic subjects: a new approach in the treatment of diabetes. Exp. Opin. Invest. Drugs, 1999, 8, 1683-1707.
24. Gaziano, J.M.; Cincotta, A.H.; O'Connor, C.M.; Ezrokhi, M.; Rutty, D.; Ma, Z.J.; Scranton, R.E. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care, 2010, 33, 1503-1508.
25. Aminorroaya, A.; Janghorbani, M.; Ramezani, M.; Haghighi, S.; Amini, M. Does bromocriptine improve glycemia control of obese type-2 diabetics? Horm. Res., 2004, 62, 55-59.
26. Vermont Price Disclosure-cycloset.com/pdf/vermontpricedisclosure. Accessed December 14, 2010.